Shark variable new antigen receptor biologics

a novel technology platform for therapeutic drug development

Marina Kovaleva, Laura Ferguson, John Steven, Andrew Porter, Caroline Barelle

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Introduction: Biologics drugs have succeeded in achieving a commercial dominance in the global market for new therapies and large pharmaceutical companies' interest remains strong through a continued commitment to pipeline development. It is not surprising, therefore, that next-generation biologics, particularly antibody-like scaffolds that offer many of the advantages of the original biologic drugs but in simplified formats, have entered the clinic as competing substitute therapeutic products, to capture market share. Areas covered: Specifically, this paper will position shark-derived variable new antigen receptors (VNARs) within an overview of the existing biologics landscape including the growth, diversity and success to date of alternative scaffolds. The intention is not to provide a comprehensive review of biologics as a whole but to discuss the main competing single-domain technologies and the exciting therapeutic potential of VNAR domains as clinical candidates within this context. Expert opinion: The inherent ability to specifically bind target and intervene in disease-related biological processes, while reducing off-site toxicity, makes mAbs an effective, potent and now proven class of therapeutics. There are, however, limitations to these 'magic bullets'. Their size and complexity can restrict their utility in certain diseases types and disease locations. In contrast, a number of so-called alternative scaffolds, derived from both immunoglobulin- and non-immunoglobulin-based sources have been developed with real potential to overcome many of the shortcomings documented for mAb treatments. Unlike competing approaches such as Darpins and Affibodies, we now know that shark VNAR domains (like camel VHH nanobody domains), are an integral part of the adaptive immune system of these animals and have evolved naturally (but from very different starting molecules) to exhibit high affinity and selectivity for target. In addition, and again influenced by the environment in which they have evolved naturally, their small size, simple architecture, high solubility and stability, deliver additional flexibility compared to classical antibodies (and many non-natural alternative scaffolds), thereby providing an attractive basis for particular clinical indications where these attributes may offer advantages.

Original languageEnglish
Pages (from-to)1527-1539
Number of pages13
JournalExpert opinion on biological therapy
Volume14
Issue number10
Early online date4 Aug 2014
DOIs
Publication statusPublished - 2014

Fingerprint

Sharks
Antigen Receptors
Biological Products
Scaffolds
Technology
Pharmaceutical Preparations
Single-Domain Antibodies
Antibodies
Immune system
Biological Phenomena
Therapeutics
Camelus
Magic
Aptitude
Toxicity
Expert Testimony
Immunoglobulins
Animals
Solubility
Pipelines

Keywords

  • binding domains
  • biologics
  • drug development
  • mAb
  • novel
  • scaffolds
  • shark
  • variable new antigen receptor

Cite this

Shark variable new antigen receptor biologics : a novel technology platform for therapeutic drug development. / Kovaleva, Marina; Ferguson, Laura; Steven, John; Porter, Andrew; Barelle, Caroline.

In: Expert opinion on biological therapy, Vol. 14, No. 10, 2014, p. 1527-1539.

Research output: Contribution to journalArticle

Kovaleva, Marina ; Ferguson, Laura ; Steven, John ; Porter, Andrew ; Barelle, Caroline. / Shark variable new antigen receptor biologics : a novel technology platform for therapeutic drug development. In: Expert opinion on biological therapy. 2014 ; Vol. 14, No. 10. pp. 1527-1539.
@article{fec1e17920aa41589160fa0a771042ff,
title = "Shark variable new antigen receptor biologics: a novel technology platform for therapeutic drug development",
abstract = "Introduction: Biologics drugs have succeeded in achieving a commercial dominance in the global market for new therapies and large pharmaceutical companies' interest remains strong through a continued commitment to pipeline development. It is not surprising, therefore, that next-generation biologics, particularly antibody-like scaffolds that offer many of the advantages of the original biologic drugs but in simplified formats, have entered the clinic as competing substitute therapeutic products, to capture market share. Areas covered: Specifically, this paper will position shark-derived variable new antigen receptors (VNARs) within an overview of the existing biologics landscape including the growth, diversity and success to date of alternative scaffolds. The intention is not to provide a comprehensive review of biologics as a whole but to discuss the main competing single-domain technologies and the exciting therapeutic potential of VNAR domains as clinical candidates within this context. Expert opinion: The inherent ability to specifically bind target and intervene in disease-related biological processes, while reducing off-site toxicity, makes mAbs an effective, potent and now proven class of therapeutics. There are, however, limitations to these 'magic bullets'. Their size and complexity can restrict their utility in certain diseases types and disease locations. In contrast, a number of so-called alternative scaffolds, derived from both immunoglobulin- and non-immunoglobulin-based sources have been developed with real potential to overcome many of the shortcomings documented for mAb treatments. Unlike competing approaches such as Darpins and Affibodies, we now know that shark VNAR domains (like camel VHH nanobody domains), are an integral part of the adaptive immune system of these animals and have evolved naturally (but from very different starting molecules) to exhibit high affinity and selectivity for target. In addition, and again influenced by the environment in which they have evolved naturally, their small size, simple architecture, high solubility and stability, deliver additional flexibility compared to classical antibodies (and many non-natural alternative scaffolds), thereby providing an attractive basis for particular clinical indications where these attributes may offer advantages.",
keywords = "binding domains, biologics, drug development, mAb, novel, scaffolds, shark, variable new antigen receptor",
author = "Marina Kovaleva and Laura Ferguson and John Steven and Andrew Porter and Caroline Barelle",
year = "2014",
doi = "10.1517/14712598.2014.937701",
language = "English",
volume = "14",
pages = "1527--1539",
journal = "Expert opinion on biological therapy",
issn = "1744-7682",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Shark variable new antigen receptor biologics

T2 - a novel technology platform for therapeutic drug development

AU - Kovaleva, Marina

AU - Ferguson, Laura

AU - Steven, John

AU - Porter, Andrew

AU - Barelle, Caroline

PY - 2014

Y1 - 2014

N2 - Introduction: Biologics drugs have succeeded in achieving a commercial dominance in the global market for new therapies and large pharmaceutical companies' interest remains strong through a continued commitment to pipeline development. It is not surprising, therefore, that next-generation biologics, particularly antibody-like scaffolds that offer many of the advantages of the original biologic drugs but in simplified formats, have entered the clinic as competing substitute therapeutic products, to capture market share. Areas covered: Specifically, this paper will position shark-derived variable new antigen receptors (VNARs) within an overview of the existing biologics landscape including the growth, diversity and success to date of alternative scaffolds. The intention is not to provide a comprehensive review of biologics as a whole but to discuss the main competing single-domain technologies and the exciting therapeutic potential of VNAR domains as clinical candidates within this context. Expert opinion: The inherent ability to specifically bind target and intervene in disease-related biological processes, while reducing off-site toxicity, makes mAbs an effective, potent and now proven class of therapeutics. There are, however, limitations to these 'magic bullets'. Their size and complexity can restrict their utility in certain diseases types and disease locations. In contrast, a number of so-called alternative scaffolds, derived from both immunoglobulin- and non-immunoglobulin-based sources have been developed with real potential to overcome many of the shortcomings documented for mAb treatments. Unlike competing approaches such as Darpins and Affibodies, we now know that shark VNAR domains (like camel VHH nanobody domains), are an integral part of the adaptive immune system of these animals and have evolved naturally (but from very different starting molecules) to exhibit high affinity and selectivity for target. In addition, and again influenced by the environment in which they have evolved naturally, their small size, simple architecture, high solubility and stability, deliver additional flexibility compared to classical antibodies (and many non-natural alternative scaffolds), thereby providing an attractive basis for particular clinical indications where these attributes may offer advantages.

AB - Introduction: Biologics drugs have succeeded in achieving a commercial dominance in the global market for new therapies and large pharmaceutical companies' interest remains strong through a continued commitment to pipeline development. It is not surprising, therefore, that next-generation biologics, particularly antibody-like scaffolds that offer many of the advantages of the original biologic drugs but in simplified formats, have entered the clinic as competing substitute therapeutic products, to capture market share. Areas covered: Specifically, this paper will position shark-derived variable new antigen receptors (VNARs) within an overview of the existing biologics landscape including the growth, diversity and success to date of alternative scaffolds. The intention is not to provide a comprehensive review of biologics as a whole but to discuss the main competing single-domain technologies and the exciting therapeutic potential of VNAR domains as clinical candidates within this context. Expert opinion: The inherent ability to specifically bind target and intervene in disease-related biological processes, while reducing off-site toxicity, makes mAbs an effective, potent and now proven class of therapeutics. There are, however, limitations to these 'magic bullets'. Their size and complexity can restrict their utility in certain diseases types and disease locations. In contrast, a number of so-called alternative scaffolds, derived from both immunoglobulin- and non-immunoglobulin-based sources have been developed with real potential to overcome many of the shortcomings documented for mAb treatments. Unlike competing approaches such as Darpins and Affibodies, we now know that shark VNAR domains (like camel VHH nanobody domains), are an integral part of the adaptive immune system of these animals and have evolved naturally (but from very different starting molecules) to exhibit high affinity and selectivity for target. In addition, and again influenced by the environment in which they have evolved naturally, their small size, simple architecture, high solubility and stability, deliver additional flexibility compared to classical antibodies (and many non-natural alternative scaffolds), thereby providing an attractive basis for particular clinical indications where these attributes may offer advantages.

KW - binding domains

KW - biologics

KW - drug development

KW - mAb

KW - novel

KW - scaffolds

KW - shark

KW - variable new antigen receptor

U2 - 10.1517/14712598.2014.937701

DO - 10.1517/14712598.2014.937701

M3 - Article

VL - 14

SP - 1527

EP - 1539

JO - Expert opinion on biological therapy

JF - Expert opinion on biological therapy

SN - 1744-7682

IS - 10

ER -